HCM vs. PBH, RARE, XENE, IDYA, JANX, AXSM, ARWR, BHVN, FOLD, and SMMT
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), Janux Therapeutics (JANX), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), Biohaven (BHVN), Amicus Therapeutics (FOLD), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical preparations" industry.
Prestige Consumer Healthcare (NYSE:PBH) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
HUTCHMED has a net margin of 0.00% compared to HUTCHMED's net margin of -7.11%. HUTCHMED's return on equity of 14.09% beat Prestige Consumer Healthcare's return on equity.
99.9% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
HUTCHMED has lower revenue, but higher earnings than Prestige Consumer Healthcare.
Prestige Consumer Healthcare currently has a consensus price target of $110.00, indicating a potential upside of 57.53%. HUTCHMED has a consensus price target of $29.70, indicating a potential upside of 52.54%. Given HUTCHMED's higher probable upside, research analysts plainly believe Prestige Consumer Healthcare is more favorable than HUTCHMED.
Prestige Consumer Healthcare received 169 more outperform votes than HUTCHMED when rated by MarketBeat users. Likewise, 70.67% of users gave Prestige Consumer Healthcare an outperform vote while only 66.74% of users gave HUTCHMED an outperform vote.
In the previous week, Prestige Consumer Healthcare had 5 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for Prestige Consumer Healthcare and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.18 beat Prestige Consumer Healthcare's score of 0.53 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.
Prestige Consumer Healthcare has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Summary
Prestige Consumer Healthcare beats HUTCHMED on 9 of the 16 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
